This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

Pat Phillips

JAMA. 1999;281:2075-2076.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Venice—The quest continues for new drugs to prevent and treat stroke.

"There are new and emerging issues in stroke prevention and pharmacological therapy, particularly antiplatelet strategies, which have progressed and which may improve on the established effects of aspirin in the prevention of stroke in patients with ischemic events," Michael G. Hennerici, MD, of the University of Heidelberg, said at the Eighth European Stroke Conference held here in April.

Antiplatelet therapies are one focus of drug development and testing, neuroprotective agents represent a second avenue, and thrombolytic agents constitute a third approach.

Time out for different strokes in Venice. (Photo credit: Pat Phillips)

ANTIPLATELET STRATEGIES

"Two new approaches to antiplatelet therapy—clopidogrel and a combination of aspirin and dipyridamole—in the secondary prevention of stroke are up to twice as good as aspirin alone," said Stephen Davis, MD, director of neurology at Royal Melbourne Hospital in Victoria, Australia. Citing . . . [Full Text of this Article]